Status:
UNKNOWN
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
Lead Sponsor:
Samsung Medical Center
Conditions:
Squamous NSCLC
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Efficacy of Dovitinib for Squamous NSCLC.
Eligibility Criteria
Inclusion
- histologically confirmed squamous NSCLC
- Previously treated with one or two lines of chemotherapy
- FGFR amplification (FISH \> 5 copies of genes)
- 20 years or older
- ECOG PS 0-2
Exclusion
- active infection
- uncontrolled brain metastasis
- unstable angina or MI
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01861197
Start Date
March 1 2013
Last Update
May 23 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710